Since EGFR-TKIs were developed and subsequently applied in the clinic, the survival and clinical outcomes of EGFR-mutated NSCLC patients have remarkably improved, and as a consequence, EGFR-TKIs are recommended as the standard first-line treatment in NSCLC patients with EGFR mutations [7, 8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.